For acute low back pain, there is moderate-certainty evidence that nonsteroidal anti-inflammatory drugs are an effective ...

A data analysis published in a scientific journal indicates that differences with placebo are marginal for most treatments ...

In a separate raid, the DCA conducted raids on clinics operated by two quacks and seized illegally stocked medicines intended ...

The American College of Physicians strongly recommends adding a triptan to an NSAID to treat adults with moderate to severe ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

The nonsteroidal anti-inflammatory drug (NSAID) flunixin meglumine has been approved by the FDA for fever associated with ...

Scientists at the University of South Australia have come up with an innovative solution to improve the effectiveness of cannabidiol to treat epilepsy, multiple sclerosis and other neurodegenerative ...

Cannabidiol is widely prescribed for its analgestic and anti inflammatory properties.Scientists at the University of South ...

After recovering from Oropouche infection, symptoms recur in about 60% of patients within a few days up to several weeks.

But a new study has found that only one in 10 treatments for lower back pain are effective, with those that improve symptoms ...

They found that just one treatment for acute low back pain and five treatments for chronic – or long-term – back pain were ...

New Delhi: Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...